Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.59 |
| ▸ | ARG2 | P78540 | 1/20 | 0.59 |
| ▸ | GGT1 | P19440 | 1/20 | 0.54 |
| ▸ | ODC1 | P11926 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162369 | 1.00 | ARG1 (0.59) | ARG1ARG2GGT1ODC1BLM | |
| SCHEMBL162370 | 1.00 | ARG1 (0.59) | ARG1ARG2GGT1ODC1BLM | |
| Hydrochloric Acid SCHEMBL11675620 | 0.98 | ARG1 (0.57) | ARG1ARG2GGT1ODC1BLM | |
| Water SCHEMBL7726696 | 0.98 | ARG1 (0.57) | ARG1ARG2GGT1ODC1BLM | |
| Water SCHEMBL7726693 | 0.98 | ARG1 (0.57) | ARG1ARG2GGT1ODC1BLM | |
| Hydrochloric Acid SCHEMBL8707966 | 0.98 | ARG1 (0.57) | ARG1ARG2GGT1ODC1BLM | |
| Hydrochloric Acid SCHEMBL3219766 | 0.98 | ARG1 (0.57) | ARG1ARG2GGT1ODC1BLM | |
| Hydrochloric Acid SCHEMBL6958032 | 0.96 | ARG1 (0.55) | ARG1ARG2GGT1ODC1BLM | |
| Hydrochloric Acid SCHEMBL6958034 | 0.96 | ARG1 (0.55) | ARG1ARG2GGT1ODC1BLM | |
| Hydrochloric Acid SCHEMBL6958028 | 0.96 | ARG1 (0.55) | ARG1ARG2GGT1ODC1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 713 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169403-B9 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | claimed |
| EP-3169403-B1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-02-14 | — | — | EP | claimed |
| WO-2023085973-A1 | PHARMACUETICAL COMPOSITIONS FOR TREATING INFLAMMATORY INFECTIOUS DISEASES | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" | 2023-05-19 | — | — | WO | claimed |
| US-20220226496-A1 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2022-07-21 | — | — | US | claimed |
| EP-3964236-A1 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE | LegoChem Biosciences, Inc. (KR) | 2022-03-09 | — | — | EP | claimed |
| CN-113727734-A | Ligand-drug conjugates comprising a linker having a tris structure | 乐高化学生物科学股份有限公司 | 2021-11-30 | — | — | CN | claimed |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-11-09 | — | — | US | claimed |
| EP-3380125-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LegoChem Biosciences, Inc. (KR) | 2018-10-03 | — | — | EP | claimed |
| WO-2017089894-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | claimed |
| US-20170007532-A1 | Cosmetic Products for Reducing Hair Appearance | THE PROCTER & GAMBLE COMPANY | 2017-01-12 | — | — | US | claimed |
| US-20070196350-A1 | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment | BAUSCH & LOMB INCORPORATED | 2007-08-23 | — | — | US | claimed |
| US-20070184151-A1 | Use of a polyamine-poor composition for the production of a medical human food | UNIVERSITE DE RENNES 1 (FR) | 2007-08-09 | — | — | US | claimed |
| EP-0920307-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1999-06-09 | — | — | EP | claimed |
| US-5872104-A | BACTERICIDES AND RESISTANT BACTERIA WITH METHYLATION INHIBITORS | ORIDIGM CORPORATION (US) | 1999-02-16 | — | — | US | claimed |
| EP-0703731-B1 | FOOD AND/OR PHARMACEUTICAL COMPOSITION HAVING A LOW POLYAMINE CONTENT, AND THERAPEUTICAL USES THEREOF | UNIV RENNES (FR) | 1998-04-08 | — | — | EP | claimed |
| WO-1998006386-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | ROCHE DIAGNOSTICS GMBH (DE) | 1998-02-19 | — | — | WO | claimed |
| EP-0703732-B1 | FOOD AND/OR PHARMACEUTICAL COMPOSITION HAVING A LOW POLYAMINE CONTENT | UNIV RENNES (FR) | 1997-09-17 | — | — | EP | claimed |
| CN-1126999-A | Peptide compounds having oxytocin antagonist activity | FERRING BV (NL) | 1996-07-17 | — | — | CN | claimed |
| WO-1996020010-A1 | COMBINATION FOR REDUCING ANTIMICROBIAL RESISTANCE USING A METHYLATION INHIBITOR IN COMBINATION WITH AN ANTIBIOTIC | ORIDIGM CORPORATION (US) | 1996-07-04 | — | — | WO | claimed |
| US-4751348-A | USING ULTRAVIOLET LIGHT MUTAGEN, POLYAMINE SYNTEHSIS INHIBITORS, AND GROWTH IN THE DARK | COLD SPRING HARBOR LABORATORY (US) | 1988-06-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | DAO, LPO, TYRO3 | ARG1 404/4885ARG2 593/4885GGT1 1183/4885 |
| US-20220226496-A1 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE | TNFSF10, TNFRSF9, ANTXR2 | ARG1 4602/4885ARG2 4664/4885GGT1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.